Document is current
Any future updates will be listed below
-
Authors
Hu, Hui-Hui
Wang, Xuefeng https://orcid.org/0000-0003-3613-6113
Lan, Bin
Cheng, Haili
Wen, Hong
Chen, Fangfang
Wu, Jianfeng
Li, Mengqi https://orcid.org/0000-0002-1171-5648
Chen, Jiazhou
Zhang, Jinhui
Chen, Dongxu
Lin, Shiyu
Lin, Jieyu
Yang, Mingyang
Wu, Zhenhua
Zheng, Zhong-Zheng
Chen, Fuqing
Zhou, Jianyin
Chen, Gang https://orcid.org/0000-0003-2540-8232
Chen, Yu
Deng, Xianming https://orcid.org/0000-0002-9354-5864
Zhang, Chen-Song https://orcid.org/0000-0001-5218-0101
Liu, Jingfeng
Lin, Sheng-Cai https://orcid.org/0000-0003-1993-8376
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (#82088102)
National Natural Science Foundation of China (#32471223)
- License Information
-
More Information
Article History
Received: 14 March 2025
Accepted: 11 September 2025
First Online: 25 November 2025
Competing interests
: The compounds described in this paper have been filed for a patent application (WO 2018184561). The authors X.D., C.-S.Z. and S.-C.L. are listed as inventors of the patent (WO 2018184561) on the therapeutic use of aldometanib and other aldometanib derivatives. All other authors declare no competing interests.
